Drugs / SARS-CoV-2 DNA Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05904054 | Jun → Dec 2023 | COVID-19 | Immuno Cure 3 Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 DNA Vaccine | “The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL.” NCT05904054 ↗ |
| Known as | ICCOV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05904054 ↗ |
| Route | Intramuscular | “Participants were administered with a single dose of 2 mg ICCOV intramuscularly” PMID 40245494 ↗ Apr 2025 |